权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

STUDIES TO EVALUATE THE POTENTIAL FOR ENVIRONMENTAL&THERAPEUTIC AGENTS TO INDUCE IMMUNOTOXICITY - In vitro immunomodulation

评估环境潜力的研究

基本信息

批准号：
10906728
负责人：
FLORENCE BURLESON
金额：
$ 21.65万
依托单位：
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-08-13 至 2024-08-12
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10906728
关键词：
Allergens Animals Autoimmune Diseases Biological Assay Blinded Chemical Agents Chemicals Code Collaborations Communicable Diseases Contracts Data Data Collection Dermal Development Event Exposure to Food Additives Gene Expression Profiling Hazard Identification Health Health Hazards Hematopoietic Human Human Cell Line Hypersensitivity Immunologic Techniques Immunologics Immunosuppression Immunotoxicology In Vitro Laboratories Measures Methods Molecular National Toxicology Program Neoplasms Peptides Pharmaceutical Preparations Predictive Value Preparation Reporting Research Resistance Skin Structure Techniques Testing Therapeutic Agents Validation Xenobiotics dietary supplements environmental agent exposed human population immune function immune system function immunoregulation immunotoxicity in vitro Model in vitro testing in vivo keratinocyte programs respiratory response screening

项目摘要

In vitro techniques for hazard identification for potential sensitizers have been of increasing importance to the NIEHS. A research collaboration agreement with a commercial vendor was established to assess the utility of the GARDair assay to identify respiratory sensitizers. As an extension of the previously reported agency partner studies where >200 chemicals were evaluated using in vitro methods to assess their potential to induce skin sensitization, NIEHS requested nominations from partner agencies to evaluate the use of an in vitro method to evaluate chemicals for their potential to induce allergic responses in the lung. The GARDair assay uses a gene set that has potential for identifying respiratory sensitizers. Agency partners nominated a total of 100 chemicals to be tested, including known respiratory sensitizers as well as chemicals of unknown potential to induce sensitization. BRT completed procurement of the chemicals in FY23 and the laboratory studies are ongoing. To date, 20 chemicals have passed range finder assays and the main runs are completed. NIEHS funded BRT participation in validation trials for the Electrophilic Allergen Screening Assay (EASA). This assay uses non-protein/peptide probes in a cell-free assessment to measure the ability of a test substance to “react” with biologically important molecules for the identification of electrophilic allergic contact dermatitis hazards. Data collection for these chemicals was completed in FY22 and the study method transfer and validation reports were completed and closed in FY23.

潜在致敏剂的体外危险识别技术对NIEHS越来越重要。与一家商业供应商达成了一项研究合作协议，以评估GARDair试验在鉴定呼吸道敏感剂方面的效用。作为之前报道的机构合作伙伴研究的延伸，&gt；200种化学物质使用体外方法进行评估，以评估它们诱导皮肤过敏的可能性，NIEHS要求合作机构提名评估体外方法的使用，以评估化学物质在肺部引发过敏反应的可能性。GARDair检测使用了一组有可能识别呼吸道敏感剂的基因组。该机构的合作伙伴共提名了100种化学品进行测试，其中包括已知的呼吸道敏感剂以及潜在致敏潜力未知的化学品。BRT在23财年完成了化学品的采购，实验室研究正在进行中。到目前为止，已有20种化学物质通过了测距仪检测，主要运行已经完成。NIEHS资助BRT参与亲电过敏原筛查试验(EASA)的验证试验。该检测方法在无细胞评估中使用非蛋白质/多肽探针，以测量测试物质与生物重要分子“反应”的能力，以确定亲电变态反应性接触性皮炎的危险。这些化学品的数据收集工作已于2012财年完成，研究方法转让和验证报告已于2013财年完成并结束。